Advances in Tardive Dyskinesia: A Review of Recent Literature

Article

In the past three years, the U.S. Food and Drug Administration has approved two medications for tardive dyskinesia, contributing to a resurgent interest in recognition, management, and treatment.

This Psychiatric Times® supplement provides a brief review of primarily recent literature on tardive dyskinesia, including signs and symptoms, risk factors and epidemiology, potential mechanisms, and screening and treatment.

Download Supplement

 

Related Videos
Dune Part 2
grave
heart
uncertainty
pray
leaders
medical student
bystander
fish river
© 2024 MJH Life Sciences

All rights reserved.